Sign in to view content

Relationship Between Number of Intermediate-Large Drusen and Geographic Atrophy Lesion Growth Rate in the Sham Groups of the DERBY, OAKS, and FILLY Trials

Eleonora Lad, MD, PhD

Video
Published 2022

Related

Baseline Characteristics in the Phase 2 GOLDEN Study of IONIS-FB-LRx, an Investigational Antisense Oligonucleotide Designed to Treat AMD-Associated Geographic Atrophy
Glenn J. Jaffe, MD
Annual Meeting Talks
2022
Geographic Atrophy in the Canadian Treat and Extend Trial With Ranibizumab in nAMD Patients: CANTREAT Study 24-Month Results
Peter J. Kertes, MD, FRCS(C)
Annual Meeting Talks
2019
How Do I Decide to Treat Patients with Geographic Atrophy?
Glenn J. Jaffe, MD
Updates from the Field
2024

Category: AMD-Non-Neovascular

See more